Colorado Prescription Drug Affordability Review Board & Advisory Council
Colorado’s Prescription Drug Affordability Board (PDAB), established under Senate Bill 21-175 and updated under House Bill 23-1225, is a Type-1 Board within the Division of Insurance that has the authority to review prescription drug costs and evaluate their impact on Coloradans through affordability reviews of prescription drugs. The Board may then recommend ways to address those costs and may set an upper payment limit for certain prescription drugs.
Prescription Drug Affordability Advisory Council (PDAAC) applications are open.
The PDAAC is currently recruiting new council members to represent the following stakeholders: Labor unions, health care professionals with prescribing authority, and manufacturers of generic drugs.
If you are interested in serving a 3-year term on the PDAAC, please fill out the linked application.
PDAB Meetings & Materials
- The next PDAB Meeting will be held Friday, December 8 at 10 am MT.
Register for December 8 PDAB Meeting
PDAAC Meetings & Materials
- The next PDAAC Meeting will be held Thursday, January 25 at 9 am MT.
Register for January 25 PDAAC Meeting
Meeting Links & Recordings
- Links to upcoming meetings and 2023 PDAB and PDAAC meeting recordings can be found here.
Contact Us
Public Comment at PDAB/PDAAC Meetings: To provide public comment at a PDAB or PDAAC meeting, please fill out the linked form. If you have difficulty accessing the form, please email dora_ins_pdab@state.co.us for assistance.
General Public Comment: To provide written comments about general PDAB business or agenda items, please fill out the linked General Public Comment Form or email dora_ins_pdab@state.co.us.
PDAB Listserv: To receive PDAB and PDAAC updates directly in your inbox, click here. To subscribe, you will need to enter your email and then choose Updates From Divisions > Division of Insurance > Division of Insurance Prescription Drug Affordability Board.
Affordability Reviews
At a high level, the affordability review process is:
On August 4, 2023, the PDAB selected the following 5 prescription drugs for affordability reviews:
- Enbrel
- Genvoya
- Cosentyx
- Stelara
- Trikafta
Next, the Board will begin the 3rd step of the affordability review process: conducting affordability reviews.
As outlined in the PDAB Affordability Review Rule and Policy, there are fourteen required components the Board must consider when conducting affordability reviews:
Data and research regarding the 14 affordability review components will be prepared for the Board’s review and any non-confidential documents will be posted on the website.
Prescription Drugs Selected for Affordability Review
Enbrel
- Affordability Review Data and Research: Coming Soon
Genvoya
- Affordability Review Data and Research: Coming Soon
Cosentyx
- Affordability Review Data and Research: Coming Soon
Stelara
- Affordability Review Data and Research: Coming Soon
Trikafta
- PDAB Members
The Prescription Drug Affordability Board (PDAB) is a 5 member Type-1 Board tasked with the following statutory duties:
Identify drugs that may be subject to an affordability review; Conduct affordability reviews on selected eligible drugs; Determine whether a prescription drug is unaffordable for Colorado consumers; If a drug is found to be unaffordable, the Board may set an upper payment limit; Make policy recommendations to the General Assembly.
The Governor has appointed the following members to the PDAB:
- Sami Diab, MD of Greenwood Village, Colorado
- Amarylis “Amy” Gutierrez, PharmD of Aurora, Colorado
- Catherine Harshbarger of Holyoke, Colorado
- Gail Mizner, MD, FACP, AAHIVS of Snowmass Village, Colorado and to serve as Board Chair
- James Justin VandenBerg, PharmD, BCPS of Denver, Colorado
- PDAAC Members
The Board appointed the 15 member Prescription Drug Affordability Advisory Council (PDAAC) to provide stakeholder input on prescription drug affordability. All PDAAC members meet statutory requirements for composition, geographic representation, and subject matter expertise.
To the extent possible, the Board appointed members who have experience serving underserved communities and who reflect the state’s diversity in terms of race, immigration status, income, disability, age, gender identity, and geography.
Council Members:
- Kim Bimestefer Executive Director of HCPF
- Gail deVore representing health care consumers
- Sarita Parikh representing health care consumers
- Edward A. Dauer, LL.B., M.P.H. representing statewide health care advocacy organizations
- Kimberley Jackson, DO representing consumers with chronic diseases and PDAAC Chair
- Applications open for individuals representing a labor union
- Nathan Wilkes representing employers
- Chad Friday representing carriers
- Marc Reece representing pharmacy benefit managers
- Applications open for individuals representing health care professionals with prescribing authority
- R. Brett McQueen, PhD representing an organization that researches prescription drugs
- Katelin Lucariello MPH representing manufacturers of brand name drugs
- Neal Miller representing manufacturers of generic drugs
- Andrew Gonzales, PharmD representing pharmacists
- Leah Lindahl representing wholesalers
- Conflicts of Interest
Information required to be disclosed pursuant to §10-16-1402(3)(d) will be contained here.
- Colorado PDAB 2023 Eligible Drug Dashboard
- Learning Series & Resources
Slides and recordings for the five part Prescription Drug Affordability Learning Series can be found below.
Learning Series 1: Data Deep Dive
Learning Series 2: Patient Perspectives
Learning Series 3: Pharmaceutical Supply Chain Panel
View Pharmaceutical Supply Chain Panel
Learning Series 4: Comparative Effectiveness & Affordability
View Comparative Effectiveness & Affordability
Learning Series 5: Prescription Drug Affordability Efforts in Colorado & Other States
View Prescription Drug Affordability Efforts in Colorado & Other States
Resources
Reducing Prescription Drug Costs in Colorado, 2nd Edition
CIVHC Top 100 Brand and Generic Commercial Payer Prescription Drugs